FDA Finally Revokes Emergency COVID-Flu Tests from Pfizer Era
Published Date: 1/2/2026
Notice
Summary
The FDA has officially ended the emergency use of two COVID-19 and flu tests made by Pfizer, effective October 22, 2025. This change affects anyone using these specific tests, as they’re no longer authorized for emergency use. No extra costs or deadlines for the public, but labs and providers should switch to other approved tests.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
Pfizer Lucira Tests EUA Revoked
The FDA revoked the Emergency Use Authorizations (EUAs) for two tests: the Lucira by Pfizer COVID-19 & Flu Test and the Lucira by Pfizer COVID-19 & Flu Home Test. The revocations were effective October 22, 2025; Pfizer requested the revocations on October 10, 2025 and told FDA there were no viable test reagents remaining in the United States.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2025-24152 — Fisheries of the South Atlantic; Southeast Data, Assessment, and Review; Public Meeting
Fishermen, seafood lovers, and coastal communities, listen up! The government is holding a public online meeting on January 20, 2026, to check the health of South Atlantic red snapper fish. This review helps decide fishing rules to keep the fish population strong and fishing sustainable, which could affect how much fish can be caught and when.
Next: 2025-24156 — Silicon Metal From Russia; Determination
The U.S. International Trade Commission decided to keep extra taxes on silicon metal imported from Russia because removing them could hurt American businesses. This means companies in the U.S. that make or use silicon metal are protected from unfairly cheap Russian imports. The decision was finalized at the end of 2025 and keeps the current rules in place for now.